Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and
toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell
disease (SCD). Based on their age and entry criteria patients are stratified into two groups:
(1) children with SCD with strokes; and (2) adults with severe SCD.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program